Tag: clinical trials

Psychedelic Drugs Market Research Report 2025-2033 | Rising Demand for Non-Hallucinogenic Psychedelics Expands Patient Base, Breakthrough Regulatory Designations Accelerate Approvals

Key opportunities in the psychedelic drugs market include rising demand for mental health treatments, especially for conditions like depression and PTSD. Advances in clinical trials and regulatory support enhance acceptance, while integration with digital health tools augments care. Global policy reforms and decriminalization further bolster growth prospects.

Key opportunities in the psychedelic drugs market include rising demand for mental health treatments, especially for conditions like depression and PTSD. Advances in clinical trials and regulatory support enhance acceptance, while integration with digital health tools augments care. Global policy reforms and decriminalization further bolster growth prospects.

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

– Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 –

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a...

Biofrontera Inc. Reports Second Quarter 2025 Financial Results and Provides a Business Update

Woburn, MA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy in dermatology, today reported financial results for the three and six months ended June 30, 2025 and provided a business update.

Applied Therapeutics Reports Second Quarter 2025 Financial Results

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

HopeAI Showcases AI-Powered Synthetic Data to Speed Up Cancer Drug Trials at ASCO 2025

NEW YORK, Aug. 13, 2025 /PRNewswire/ -- HopeAI , a Mayo Clinic Platform Accelerate company, is advancing how cancer clinical trials are designed and...

MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States

MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products. MediPharm...

HopeAI Joins Mayo Clinic Platform to Transform the Future of Drug Development with AI

NEW YORK, Aug. 12, 2025 /PRNewswire/ -- HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined...

Wong To Yick Wood Lock Medicated Balm Proudly Announces Cantopop Diva Joey Yung as Its First-Ever Brand Ambassador

"No.1 Meets No.1" – A Legendary Collaboration Redefining Excellence HONG KONG, Aug. 13, 2025 /PRNewswire/ -- Renowned Hong Kong heritage brand Wong To Yick Wood...

KBP’s Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration

SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International...

OIKOS® Launches First-of-Its-Kind Cultured Dairy Drink Featuring A Patented Blend of Nutrients Designed to Help Build & Retain Muscle Mass During Weight Loss

New OIKOS FUSION™ is the first product in the yogurt category with a proprietary combination of whey, leucine and vitamin D designed to support...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsClinical trials

Persist AI Teams up with Microsize and Micromacinazione (Micmac) to Launch First-of-Its-Kind Early-Stage “Micromill” Formulation Platform, Enabling Drug Development Decision With Milligrams of API

READY FOR LAUNCH: GOODYEAR HEADS BACK TO THE MOON

Digital University Unveils New LMS/SIS Capabilities